Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Liabilities (2018 - 2025)

Revolution Medicines has reported Total Liabilities over the past 8 years, most recently at $723.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $723.2 million for Q4 2025, up 146.75% from a year ago — trailing twelve months through Dec 2025 was $723.2 million (up 146.75% YoY), and the annual figure for FY2025 was $723.2 million, up 146.75%.
  • Total Liabilities for Q4 2025 was $723.2 million at Revolution Medicines, up from $655.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for RVMD hit a ceiling of $723.2 million in Q4 2025 and a floor of $89.0 million in Q2 2021.
  • Median Total Liabilities over the past 5 years was $145.6 million (2022), compared with a mean of $234.3 million.
  • Biggest five-year swings in Total Liabilities: decreased 8.16% in 2023 and later surged 233.01% in 2025.
  • Revolution Medicines' Total Liabilities stood at $135.4 million in 2021, then fell by 6.41% to $126.7 million in 2022, then surged by 85.82% to $235.5 million in 2023, then increased by 24.45% to $293.1 million in 2024, then surged by 146.75% to $723.2 million in 2025.
  • The last three reported values for Total Liabilities were $723.2 million (Q4 2025), $655.0 million (Q3 2025), and $564.2 million (Q2 2025) per Business Quant data.